Full Text View
Tabular View
No Study Results Posted
Related Studies
The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
This study is currently recruiting participants.
Study NCT00035893   Information provided by Hemispherx Biopharma
First Received: May 6, 2002   Last Updated: September 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Seropositivity
HIV Infection
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Communicable Diseases
HIV Infections
Infection
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
(Ampligen) polyI-polyC12U
Additional drug interventions recognized in this trial
Ampligen
More general drug interventions related to this trial
Anti-Infective Agents
Antiviral Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Hemispherx Biopharma


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services